Marquet Magda 4

What Happened

• Magda Marquet, a director of First Tracks Biotherapeutics, was granted derivative awards on 2026-05-12: 15,000 restricted stock units (RSUs) and an award covering 42,000 shares (derivative/option-type award). The awards were reported at $0.00 per share (no cash paid on grant). These are awards (code A) rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-05-12; Form 4 filed: 2026-05-14 (filed two days after the transaction).
• Reported price: $0.00 per share (award/grant); reported acquisition value $0 on the Form 4 (this reflects grant accounting, not the market value of potential shares).
• Vesting/settlement notes:
  • The 15,000 RSUs: each RSU represents a contingent right to 1 share; vests 100% on the issuer’s 2027 annual meeting date, subject to continued service. (Footnotes F1–F2)
  • The 42,000-share award: treated as options that vest 1/12 monthly beginning June 12, 2026 until fully vested, subject to continued service. (Footnote F3)
  • In addition to the 42,000-share award, the reporting person holds options to purchase up to an additional aggregate of 70,104 shares that vest per their separate terms. (Footnote F4)
• Shares owned after the transactions: not specified in the provided filing excerpt.

Context

• These were grant/award transactions (derivative awards), not open-market buys or sales. RSUs represent a future right to receive shares at settlement; options vest over time and do not indicate an immediate sale or purchase of underlying stock.
• Awards reported at $0 on Form 4 reflect the grant/award nature; they do not show the potential market value of the vested shares or options. No sale or exercise was reported in this filing.